Pricing Log in Create free account

Keros Therapeutics, Inc. (KROS) vs Sol-Gel Technologies Ltd. (SLGL)

Keros Therapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Keros Therapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($224.9M and $220.1M). Keros Therapeutics, Inc. grew revenue faster over the last twelve months: −84.6% against −92.5%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−1,345.3% vs −6,630.2%). Across the 16 metrics below, Keros Therapeutics, Inc. leads on 14 and Sol-Gel Technologies Ltd. on 2.

Valuation

Metric KROS SLGL Biotechnology median
P/E n/m n/m 8.42
P/S 6.62 124.83 10.01
P/B 0.84 4.66 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA 0.38 n/m 0.61
EV/Sales (1.14) 134.52 9.41
Earnings yield (33.33%) (8.23%) (31.85%)
Free cash flow yield (22.06%) (9.49%) (24.58%)

Profitability

Metric KROS SLGL Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (17.16%) (40.85%) (56.36%)
Return on assets (15.92%) (35.11%) (48.04%)
Return on invested capital (1,345.30%) (6,630.24%) 0.00%

Growth

Metric KROS SLGL Biotechnology median
Revenue growth (TTM) (84.55%) (92.50%) 6.02%
EPS growth (last fiscal year) 146.00% 42.37% 30.26%
Revenue growth, 5-year CAGR 89.45% 17.19% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KROS SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.96 10.37 4.72
Net debt to EBITDA (4.16) 3.23 0.96

Dividend

Metric KROS SLGL Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric KROS SLGL Biotechnology median
Market cap 220.08m 224.92m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack